Polypharmacy, when a number of drugs are co-administered, is more common, especially among the elderly and the chronically ill.  Polypharmacy is a risk factor for adverse drug reactions (ADRs) and drug-drug interactions (DDIs). One plausible DDI occurs when a drug or its metabolites interfere with the metabolism of another, causing irreversible changes to the metabolic pathways of one or both. Such suppression or attenuation of the metabolism could cause significant variances in toxicity and / or efficacy. We report herein preliminary experiments to study and predict modulation of oxidative metabolite formation of common drugs for diabetes (e.g. Metformin), hypercholesterolemia (e.g. Atorvastatin) and hypertension (e.g., Nifedipine) in presence of each other.  Biomimiks is in vitro and ex vivo technology designed to mimic the in vivo oxidative metabolism mediated by cytochromes P-450. Biomimiks has potential to be applied at the individual patient level using chemistry-based diagnostics to determine comparative effectiveness and safety.

Chemosynthetic livers: Evaluating plausible drug-drug interactions relating to metabolite suppression or attenuation

247th National Meeting (2014)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.